ACGL Research Note — Premium Growth Faces a Test
Slower premium growth, catastrophe exposure and the rate path set the evidence test for Arch Capital through October.
CAMS Research Desk
ACGL Deep Coverage Review — Analysis as of August 4, 2026
Arch Capital remains a high-quality underwriting franchise, but slower premium growth and catastrophe risk raise the burden of proof.
SPCX Research Note — Evidence Meets Supply
SpaceX operating progress meets SPCX’s unresolved post-IPO tape as first earnings and a large August share release test public-market demand.
SPCX Deep Coverage Review — Analysis as of August 3, 2026
SpaceX has rare operating assets, but its first public report and an unprecedented share release leave SPCX sponsorship and valuation unresolved.
Market Structure: Rates Divide Market Leadership — August 4, 2026
SPY is holding its intermediate trend, but a 4.74% 10-year yield, technology weakness, and 38% watchlist breadth keep the regime mixed.
WST Research Note — Good Quarter, Harder Proof
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
WST Deep Coverage Review — Analysis as of August 3, 2026
West Pharmaceutical’s beat-and-raise supports the recovery thesis, but a heavy-volume reversal and oral-drug substitution risk keep confirmation incomplete.
MOH Research Note — Medical Costs Stay Unresolved
Molina's raised outlook faces a 92.2% medical-cost ratio, a 57% ACA membership decline and weak price structure.
MOH Deep Coverage Review — Analysis as of August 3, 2026
Molina's earnings beat faces a 92.2% medical-cost ratio, a 57% ACA membership decline and unresolved valuation evidence.
Desk Note — PLTR Clears the Earnings Bar · Aug 03
Palantir’s commercial growth and raised outlook clear the bull-case tests in the July 30 review, while valuation remains the next question.